The high response rate of tepotinib in patients with MET exon 14 skipping highlights the importance of molecular testing during NSCLC diagnosis and indicates a potentially significant role for liquid biopsies in terms of indicating patients who could benefit from tepotinib. Here, MET is linked to non-small cell lung carcinoma.